Close
  Indian J Med Microbiol
 

Figure 14: Comparison of IL-23 blockers from different trials at week 12/week 16—tildrakizumab (reSURFACE 2) and risankizumab (phase 2) at week 12; guselkumab (VOYAGE 1) at week 16

Figure 14: Comparison of IL-23 blockers from different trials at week 12/week 16—tildrakizumab (reSURFACE 2) and risankizumab (phase 2) at week 12; guselkumab (VOYAGE 1) at week 16